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Abstract
Maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 (six-event stack maize) was produced by
conventional crossing to combine six single events: Bt11, MIR162, MIR604, 1507, 5307 and GA21. The
GMO Panel previously assessed the six single events and 22 of their combinations and did not identify
safety concerns. No new data on the maize single events or their 22 combinations that could lead to
modification of the original conclusions on their safety have been identified. The molecular
characterisation, comparative analysis (agronomic, phenotypic and compositional characteristics) and
the outcome of the toxicological, allergenicity and nutritional assessment indicate that the combination of
the single maize events and of the newly expressed proteins in the six–event stack maize does not give
rise to food and feed safety and nutritional concerns. The GMO Panel concludes that the six-event stack
maize, as described in this application, is as safe as and nutritionally equivalent to its non-GM comparator
and the non-GM reference varieties tested. In the case of accidental release of viable grains of the six-
event stack maize into the environment, this would not raise environmental safety concerns. The GMO
Panel assessed the likelihood of interactions among the single events in the 34 maize subcombinations
not previously assessed and concludes that these are expected to be as safe as and nutritionally
equivalent to the single events, the previously assessed subcombinations and the six-event stack maize.
The post-market environmental monitoring plan and reporting intervals are in line with the intended uses
of the six-event stack maize. Post-market monitoring of food/feed is not considered necessary. The GMO
Panel concludes that the six-event stack maize and its subcombinations are as safe as its non-GM
comparator and the tested non-GM reference varieties with respect to potential effects on human and
animal health and the environment.
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Summary
Following the submission of application EFSA-GMO-DE-2011-103 under Regulation (EC) No 1829/2003
from Syngenta, the Panel on Genetically Modified Organisms of the European Food Safety Authority
(hereafter referred to as the ‘GMO Panel’) was asked to deliver a scientific opinion on genetically modified
(GM) maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 (hereafter referred to as ‘the six-event
stack maize’) and its subcombinations independently of their origin (referred to hereafter as
‘subcombinations’). The scope of application EFSA-GMO-DE–2011-103 is for the placing on the market of
maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 and all its subcombinations independently of
their origin for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of up to five of the events present in the six-event
stack maize. The safety of subcombinations occurring as segregating progeny in the harvested grains of
maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 is evaluated in the context of the assessment
of the six-event stack maize in Section 3.3 of the present GMO Panel scientific opinion. The safety of the
subcombinations that either have been or could be produced by conventional crossing through targeted
breeding approaches, which can be bred, produced and marketed independently of the six-event stack
maize, are risk assessed in Section 3.4 of the present scientific opinion.
In delivering its scientific opinion, the GMO Panel considered the information available on the single
events, the six-event stack maize, 25 of the subcombinations (10 two-event stacks, 10 three-event
stacks, 4 four-event stacks and a five-event stack), the scientific comments submitted by the Member
States and the relevant scientific literature. The six-event stack maize was produced by conventional
crossing to combine six single maize events: Bt11 (expressing Cry1Ab and the phosphinothricin acetyl
transferase (PAT) proteins); MIR162 (expressing the Vip3Aa20 and the phosphomannose isomerase
(PMI) proteins); MIR604 (expressing a modified Cry3A (mCry3A) and the PMI proteins); 1507
(expressing the Cry1F and the PAT proteins); 5307 (expressing the eCry3.1Ab and the PMI proteins);
and GA21 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase enzyme (mEPSPS)). Herbicide
tolerance traits are achieved by the expression of mEPSPS protein from Zea mays and PAT protein
from Streptomyces viridochromogenes. Insect resistance traits are achieved by the expression of the
Cry1Ab, Vip3Aa20 and Cry1F proteins from Bacillus thuringiensis for protection against specific
lepidopteran pests and by the expression of the mCry3A and eCry3.1Ab proteins from B. thuringiensis
for protection against corn rootworm (Diabrotica spp.) larval feeding.
The GMO Panel evaluated the six-event stack maize and its subcombinations with reference to the
scope and appropriate principles described in its guidelines for the risk assessment of GM plants and
derived food and feed, the environmental risk assessment of GM plants and the post-market
environmental monitoring (PMEM) of GM plants.
For application EFSA-GMO-DE-2011-103, previous assessments of the six single maize events Bt11,
MIR162, MIR604, 1507, 5307 and GA21 and 22 of the subcombinations (10 two-event stacks, 9 three-
event stacks and 3 four-event stacks), together with new information on three subcombinations,
provided a basis to evaluate the six-event stack maize and all its subcombinations. No safety concerns
were identified by the GMO Panel in the previous assessments. No safety issue concerning the six
single maize events was identified by the updated bioinformatic analyses, nor reported by the
applicant since the publication of the previous GMO Panel scientific opinions. Therefore, the GMO
Panel considers that its previous conclusions on the safety of the single maize events remain valid.
For the six-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analysis of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food and feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and the PMEM plan
was also undertaken.
The molecular characterisation data establish that the events stacked in maize Bt11 9 MIR162 9
MIR604 9 1507 9 5307 9 GA21 have retained their integrity. Protein expression analyses show that
the levels of the newly expressed proteins are similar in the six-event stack and in the single events or
already assessed subcombinations, except for the expected higher levels of the PAT and PMI proteins
in the six-event stack resulting from the combination of events Bt11 and 1507 (both producing PAT)
and events MIR162, 5307 and MIR604 (all producing PMI). No indications of interactions that may
affect the integrity of the events and the levels of the newly expressed proteins in this six-event stack
maize are identified.
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The comparative analysis of forage and grain composition and agronomic/phenotypic characteristics
identified no differences between maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 and the
non-GM comparator that required further assessment for food/feed safety or environmental impact,
except for the levels of ash, potassium, zinc, b-carotene, folic acid, methionine, arachidic acid (C20:0)
and ferulic acid in grain and for the agronomic/phenotypic endpoints early stand count, final stand
count, days to 50% pollen shed and grain moisture. All those changes were further assessed and not
found to have a safety impact.
The molecular characterisation, the comparative analysis and the outcome of the toxicological,
allergenicity and nutritional assessment indicate that the combination of the single maize events and of
the newly expressed proteins in the six-event stack maize does not give rise to food and feed safety and
nutritional concerns. The GMO Panel concludes that maize Bt11 9 MIR162 9 MIR604 9
1507 9 5307 9 GA21, as described in this application, is as safe as and nutritionally equivalent to its
non-GM comparator and the non-GM reference varieties tested.
Considering the events combined and their potential interactions, the outcome of the comparative
analysis and the routes and levels of exposure, the GMO Panel concludes that maize
Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 would not raise safety concerns in the case of
accidental release of viable GM maize grains into the environment.
Since no new safety concerns were identified for the 22 previously assessed subcombinations (10
two event stacks, 9 three-event stacks and 3 four-event stacks) and no new data leading to the
modification of the original conclusions on safety were identified, the GMO Panel considers that its
previous conclusions on these maize subcombinations remain valid. The remaining 34 subcombinations
included in the scope of application EFSA-GMO-DE-2011-103 have not been previously assessed; for
three of them, the applicant provided new information that was considered by the GMO Panel. The
GMO Panel assessed the possibility of interactions between the events in the 34 subcombinations and
concludes that these combinations would not raise safety concerns. These subcombinations are
therefore expected to be as safe as and nutritionally equivalent to the single events, the previously
assessed subcombinations and the six-event stack maize.
Given the absence of safety concerns for foods and feeds from maize Bt11 9 MIR162 9 MIR604 9
1507 9 5307 9 GA21 and all its subcombinations, the GMO Panel considers that post-market
monitoring of these products is not necessary. The PMEM plan and reporting intervals are in line with the
intended uses of the six-event stack maize and its subcombinations.
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1. Introduction
The scope of application EFSA-GMO-DE-2011-103 is for food and feed uses, import and processing
in the European Union (EU) of the genetically modified (GM) herbicide-tolerant insect-resistant maize
Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 and all its subcombinations independently of their
origin.
1.1. Background
On 16 December 2011, the European Food Safety Authority (EFSA) received from the Competent
Authority of Germany application EFSA-GMO-DE-2011-103 for authorisation of maize Bt11 9 MIR162 9
MIR604 9 1507 9 5307 9 GA21 (hereafter referred to as ‘the six-event stack maize’) (Unique Identifier:
SYNBTØ1119 SYNIR162-49 SYNIR6Ø4-59DAS-Ø15Ø7-19 SYN-Ø53Ø7-19MON-ØØØ21-9), submitted
by Syngenta Crop Protection AG (hereafter referred to as ‘the applicant’) according to Regulation (EC)
No 1829/20031.
Following receipt of application EFSA-GMO-DE-2011-103, EFSA informed the Member States (MS)
and the European Commission and made the summary of the application available to the public on the
EFSA website.2
EFSA checked the application for compliance with the relevant requirements of Regulation (EC)
No 1829/2003 and, when needed, asked the applicant to supplement the initial application. On 18
August 2014, EFSA declared the application valid and made the valid application available to MS and
the European Commission.
From the validity date, EFSA and its scientific Panel on Genetically Modified Organisms (hereafter
referred to as ‘the GMO Panel’) endeavoured to respect a time limit of 6 months to issue a scientific
opinion on application EFSA-GMO-DE-2011-103. Such time limit was extended whenever EFSA and/or
its GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment
was made available to the EU MS and European Commission (for further details, see the section
‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of EU MS, including national Competent Authorities within the meaning of Directive 2001/18/EC3.
The EU MS had 3 months to make their opinion known on application EFSA-GMO-DE-2011-103 as of date
of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientific risk assessment of the six-event stack maize and all its
subcombinations independently of their origin, for food and feed uses, import and processing.
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
In addition to the present scientific opinion, EFSA was also asked to report on the particulars listed
under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003, but not to give an opinion on them,
because they pertain to risk management.4
2. Data and methodologies
2.1. Data
The GMO Panel based its scientific assessment of the six-event stack maize on the valid application
EFSA-GMO-DE-2011-103, additional information provided by the applicant during the risk assessment,
scientific comments submitted by MS and relevant peer-reviewed scientific publications.
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food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00069
3 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
4 These particulars can be found in the technical report by EFSA on application EFSA-GMO-DE-2011-103, made available in the
EFSA Register of Questions.
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2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU)
No 1829/2003, its applicable guidelines (EFSA GMO Panel, 2010a, 2011a,b) and explanatory notes
(EFSA, 2017a,b) for the risk assessment of GM plants.
In the context of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatic and statistical analyses, respectively.
3. Assessment
3.1. Introduction
Application EFSA-GMO-DE-2011-103 covers the six-event stack maize Bt11 9 MIR162 9
MIR604 9 1507 9 5307 9 GA21 and all its 56 subcombinations independently of their origin
(Table 1).
The term ‘subcombination’ refers to any combination of up to five of the maize events Bt11,
MIR162, MIR604, 1507, 5307 and GA21.
The safety of subcombinations occurring as segregating progeny in harvested grains of the six-
event stack maize is evaluated in the context of the assessment of the six-event stack maize in
Section 3.3 of the present scientific opinion.
‘Subcombination’ also covers combinations that have either been or could be produced by
conventional crossing through targeted breeding approaches (EFSA GMO Panel, 2011a). These are
maize stacks that can be bred, produced and marketed independently of the six-event stack maize.
These subcombinations are assessed in Section 3.4 of this scientific opinion.
The six-event stack maize was produced by conventional crossing to combine six single maize
events: Bt11 (expressing the proteins Cry1Ab and phosphinothricin acetyl transferase (PAT)), MIR162
(expressing the proteins Vip3Aa20 and phosphomannose isomerase (PMI)), MIR604 (expressing PMI
and a modified Cry3A (mCry3A) protein), 1507 (expressing the proteins Cry1F and PAT), 5307
(expressing the proteins eCry3.1Ab and PMI) and GA21 (expressing the 5-enolpyruvylshikimate-3-
phosphate synthase enzyme (mEPSPS)).
Herbicide tolerance traits are achieved by the expression of the mEPSPS protein from Zea mays and
PAT protein from Streptomyces viridochromogenes. Insect resistance traits are achieved by the
expression of the Cry1Ab, Vip3Aa20 and Cry1F proteins from Bacillus thuringiensis for protection
against specific lepidopteran pests, and the mCry3A and eCry3.1Ab proteins from B. thuringiensis for
protection against corn rootworm (Diabrotica spp.) larval feeding.
Table 1: Stacked maize events covered by the scope of application EFSA-GMO-DE-2011-103
Degree of Stacking Events
Six-event stack maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21
Five-event stack maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307
Bt11 9 MIR162 9 MIR604 9 1507 9 GA21
Bt11 9 MIR162 9 MIR604 9 5307 9 GA21
Bt11 9 MIR162 9 1507 9 5307 9 GA21
Bt11 9 MIR604 9 1507 9 5307 9 GA21
MIR162 9 MIR604 9 1507 9 5307 9 GA21
Four-event stack maize Bt11 9 MIR162 9 MIR604 9 1507
Bt11 9 MIR162 9 MIR604 9 5307
Bt11 9 MIR162 9 MIR604 9 GA21
Bt11 9 MIR604 9 1507 9 5307
Bt11 9 MIR604 9 1507 9 GA21
Bt11 9 MIR162 9 1507 9 5307
Bt11 9 MIR162 9 1507 9 GA21
Bt11 9 MIR162 9 5307 9 GA21
Bt11 9 MIR604 9 5307 9 GA21
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All six single maize events and 22 of the subcombinations (10 two-event stacks, 9 three-event
stacks and 3 four-event stacks) have been previously assessed (see Table 2). No concerns for human
and animal health or environmental safety were identified.
Degree of Stacking Events
Bt11 9 1507 9 5307 9 GA21
MIR162 9 MIR604 9 1507 9 5307
MIR162 9 MIR604 9 1507 9 GA21
MIR162 9 MIR604 9 5307 9 GA21
MIR162 9 1507 9 5307 9 GA21
MIR604 9 1507 9 5307 9 GA21
Three-event stack maize Bt11 9 MIR162 9 MIR604
Bt11 9 MIR162 9 1507
Bt11 9 MIR162 9 5307
Bt11 9 MIR162 9 GA21
Bt11 9 MIR604 9 1507
Bt11 9 MIR604 9 5307
Bt11 9 MIR604 9 GA21
Bt11 9 1507 9 5307
Bt11 9 1507 9 GA21
Bt11 9 5307 9 GA21
MIR162 9 MIR604 9 1507
MIR162 9 MIR604 9 5307
MIR162 9 MIR604 9 GA21
MIR162 9 1507 9 5307
MIR162 9 1507 9 GA21
MIR162 9 5307 9 GA21
MIR604 9 1507 9 5307
MIR604 9 1507 9 GA21
MIR604 9 5307 9 GA21
1507 9 5307 9 GA21
Two-event stack maize Bt11 9 MIR162
Bt11 9 MIR604
Bt11 9 1507
Bt11 9 5307
Bt11 9 GA21
MIR162 9 MIR604
MIR162 9 1507
MIR162 9 5307
MIR162 9 GA21
MIR604 9 1507
MIR604 9 5307
MIR604 9 GA21
1507 9 5307
1507 9 GA21
5307 9 GA21
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Table 2: Single maize events and subcombinations of maize Bt11 9 MIR162 9 MIR604 9
1507 9 5307 9 GA21 previously assessed by the GMO Panel
Event Application or mandate EFSA Scientific Opinions
Bt11 C/F/96/05.10 EFSA (2005a)
EFSA-GMO-RX-Bt11 EFSA (2009a)
EFSA-M-2012–0232(a) EFSA GMO Panel (2012a)
MIR162 EFSA-GMO-DE-2010-82 EFSA GMO Panel (2012b)
MIR604 EFSA-GMO-UK-2005-11 EFSA (2009b)
1507 C/NL/00/10 EFSA (2004)
C/ES/01/01 EFSA (2005b)
EFSA-GMO-NL-2004-02 EFSA (2005c)
EFSA-GMO-RX-1507 EFSA (2009c)
EFSA-M-2012-0231(b) EFSA GMO Panel (2012c)
EFSA-GMO-RX-001 EFSA GMO Panel (2017a)
5307 EFSA-GMO-DE-2011-95 EFSA GMO Panel (2015a)
EFSA-M-2017-0011(c) EFSA GMO Panel (2018a)
GA21 EFSA-GMO-UK-2005-19 EFSA (2007)
EFSA-GMO-RX-GA21
EFSA-GMO-UK-2008-60 EFSA GMO Panel (2011c)
EFSA-GMO-RX-005 EFSA GMO Panel (2017b)
Bt11 9 MIR162 EFSA-GMO-DE-2009-66
EFSA-M-2016-0248(d)
EFSA GMO Panel (2015b)
EFSA GMO Panel (2017c)
Bt11 9 MIR604 EFSA-GMO-UK-2007-50 EFSA GMO Panel (2010b)
Bt11 9 1507 EFSA-GMO-DE-2011-99 EFSA GMO Panel (2016)
Bt11 9 GA21 EFSA-GMO-UK-2007-49 EFSA GMO Panel (2009)
MIR162 9 MIR604 EFSA-GMO-DE-2009-66 EFSA GMO Panel (2015b)
MIR162 9 1507 EFSA-GMO-DE-2010-86 EFSA GMO Panel (2018b)
MIR162 9 GA21 EFSA-GMO-DE-2009-66 EFSA GMO Panel (2015b)
MIR604 9 1507 EFSA-GMO-DE-2011-99 EFSA GMO Panel (2016)
MIR604 9 GA21 EFSA-GMO-UK-2007-48 EFSA GMO Panel (2010c)
1507 9 GA21 EFSA-GMO-DE-2011-99 EFSA GMO Panel (2016)
Bt11 9 MIR162 9 MIR604 EFSA-GMO-DE-2009-66 EFSA GMO Panel (2015b)
Bt11 9 MIR162 9 1507 EFSA-GMO-DE-2010-86 EFSA GMO Panel (2018b)
Bt11 9 MIR162 9 GA21 EFSA-GMO-DE-2009-66 EFSA GMO Panel (2015b)
Bt11 9 MIR604 9 GA21 EFSA-GMO-UK-2008-56 EFSA GMO Panel (2010d)
Bt11 9 MIR604 9 1507 EFSA-GMO-DE-2011-99 EFSA GMO Panel (2016)
Bt11 9 1507 9 GA21 EFSA-GMO-DE-2011-99
EFSA-M-2017-0169(e)
EFSA GMO Panel (2016)
EFSA GMO Panel (2017d)
MIR162 9 MIR604 9 GA21 EFSA-GMO-DE-2009-66 EFSA GMO Panel (2015b)
MIR162 9 1507 9 GA21 EFSA-GMO-DE-2010-86 EFSA GMO Panel (2018b)
MIR604 9 1507 9 GA21 EFSA-GMO-DE-2011-99 EFSA GMO Panel (2016)
Bt11 9 MIR162 9 MIR604 9 GA21 EFSA-GMO-DE-2009-66 EFSA GMO Panel (2015b)
Bt11 9 MIR162 9 1507 9 GA21 EFSA-GMO-DE-2010-86 EFSA GMO Panel (2018b)
Bt11 9 MIR604 9 1507 9 GA21 EFSA-GMO-DE-2011-99 EFSA GMO Panel (2016)
(a): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00713
(b): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00712
(c): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2017-00052
(d): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2016-00730
(e): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2017-00669
Assessment of maize Bt11 3 MIR162 3 MIR604 3 1507 3 5307 3 GA21 and subcombinations
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2019;17(4):5635
3.2. Updated information on the single events5
Since the publication of the scientific opinions on the single maize events (see Table 2), no safety
issue concerning any of the six events has been reported by the applicant.
The applicant clarified that the maize 1507 sequence reported in this application is identical to the
corrected maize 1507 sequence (EFSA GMO Panel, 2017a). Analysis of the corrected sequencing data
and the bioinformatic analyses performed on this sequence did not give rise to safety issues (EFSA
GMO Panel, 2017a,e).
Updated bioinformatic analyses on the junction regions for maize events Bt11, MIR162, MIR604,
1507, 5307 and GA21, performed using the methodology specified in EFSA GMO Panel (2011a),
confirm that no known endogenous genes were disrupted by any of the inserts.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed Cry1F, PAT,
Cry1Ab, Vip3Aa20, PMI, mCry3A, eCry3.1Ab and mEPSPS proteins reveal no significant similarities to
toxins and allergens. Updated bioinformatic analyses of the newly created open reading frames (ORFs)
within the insert or spanning the junctions between the insert and genomic DNA indicate that the
expression of an ORF showing significant similarities to toxins or allergens is highly unlikely.
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination,
the applicant performed a sequence identity analysis with microbial DNA for maize events Bt11,
MIR162, MIR604, 1507, 5307 and GA21. The likelihood and potential consequences of plant-to-
bacteria gene transfer are described in Section 3.3.4.2.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
3.3. Risk assessment of maize Bt11 3 MIR162 3 MIR604 3 1507 3
5307 3 GA21
3.3.1. Molecular characterisation6
Possible interactions that would affect the integrity of the events, protein expression level or the
biological function conferred by the individual inserts are considered below.
3.3.1.1. Genetics elements and their biological function
Maize events Bt11, MIR162, MIR604, 1507, 5307 and GA21 were combined by conventional crossing
to produce the six-event stack maize. The structure of the inserts in the six-event stack is described in
detail in the respective EFSA scientific opinions (Table 2) and no new genetic modifications were
involved. Genetic elements in the expression cassettes of the single events are summarised in Table 3.
Intended effects of the inserts in the six-event stack maize are summarised in Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the Vip3Aa20 protein and the four Cry
proteins and between the four Cry proteins in susceptible insects.
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5 Dossier: Part II – Section A.2.2.2; additional information: 21/7/2015, 17/12/2015, 8/6/2018, 11/6/2018, 17/8/2018 and 8/2/2019.
6 Dossier: Part II – Section A.2; additional information: 17/8/2018 and 19/12/2018.
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2019;17(4):5635
Table 3: Genetic elements in the expression cassettes of the events stacked in maize Bt11 9
MIR162 9 MIR604 9 1507 9 5307 9 GA21
Event Promoter 50 UTR
Transit
peptide
Coding region* Terminator
Bt11 35S (CaMV) IVS6
(Zea mays)
– cry1Ab
(Bacillus thuringiensis)
nos
(Agrobacterium
tumefaciens)
35S (CaMV) IVS2
(Z. mays)
– pat (Streptomyces
viridochromogenes)
nos (A. tumefaciens)
MIR162 ZmUbiInt
(Z. mays)
– – vip3Aa20
(B. thuringiensis)
35S (CaMV)
ZmUbiInt
(Z. mays)
– – pmi (Escherichia coli) nos (A. tumefaciens)
MIR604 MTL
(Z. mays)
– – mcry3A
(B. thuringiensis)
nos (A. tumefaciens)
ZmUbiInt
(Z. mays)
– – Pmi (E. coli) nos (A. tumefaciens)
1507 Ubi1ZM
(Z. mays)
– – cry1F
(B. thuringiensis)
ORF25PolyA
(A. tumefaciens)
35S (CaMV) – – pat (S. viridochromogenes) 35S (CaMV)
5307 CMP (CmYLCV) – – ecry3.1Ab
(B. thuringiensis)
nos (A. tumefaciens)
ZmUbiInt
(Z. mays)
– – pmi (E. coli) nos (A. tumefaciens)
GA21 actin 1
(Oryza sativa)
actin 1
(O. sativa)
OTP
(Helianthus
annuus)
mepsps (Z. mays) nos (A. tumefaciens)
*: Codon-optimised for expression in plants.
UTR: untranslated region; –: when no element was specifically introduced to optimise expression.
Table 4: Characteristics and intended effects of the events stacked in maize Bt11 9 MIR162 9
MIR604 9 1507 9 5307 9 GA21
Event Protein
Donor organism and biological
function
Intended effects in GM plant
Bt11 Cry1Ab Based on genes from Bacillus thuringiensis
var. kurstaki HD-1. B. thuringiensis is an
insect pathogen; its insecticidal activity is
attributed to the expression of crystal
proteins (Cry) (Schnepf et al., 1998; Ellis
et al., 2002)
Event Bt11 expresses a chimeric,
truncated cry1Ab gene. Cry1Ab is a
chimeric protein toxic to certain
lepidopteran larvae feeding on maize
PAT Based on a gene from Streptomyces
viridochromogenes T€u494. Phosphinothricin-
acetyl-transferase (PAT) enzyme acetylates
L-glufosinate-ammonium (Thompson et al.,
1987; Wohlleben et al., 1988; Eckes et al.,
1989)
Event Bt11 expresses the PAT protein
which confers tolerance to glufosinate
ammonium-based herbicides (Droge-
Laser et al., 1994)
MIR162 Vip3Aa20 Based on a gene from Bacillus thuringiensis
strain AB88 (Estruch et al., 1996). In addition
to Cry proteins, B. thuringiensis also
produces insecticidal proteins during its
vegetative growth stage. These are referred
to as vegetative insecticidal proteins (Vip)
(Fang et al., 2007)
Event MIR162 expresses a modified
version of the B. thuringiensis
vip3Aa1 gene, and encodes
Vip3Aa20, a protein toxic to certain
lepidopteran larvae feeding on maize
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Event Protein
Donor organism and biological
function
Intended effects in GM plant
PMI(a) Based on a gene from Escherichia coli. The
phosphomannose isomerase (PMI) enzyme
catalyses the isomerisation of mannose-6-
phosphate to fructose-6-phosphate and plays
a role in the metabolism of mannose
(Markovitz et al., 1967)
Event MIR162 expresses PMI, which
is used as selectable marker. Mannose
normally inhibits root growth,
respiration and germination.
Transformed cells expressing PMI are
able to utilise mannose as a carbon
source (Negrotto et al., 2000)
MIR604 mCry3A Based on genes from Bacillus thuringiensis
subsp. tenebrionis. B. thuringiensis is an
insect pathogen; its insecticidal activity is
attributed to the expression of crystal
proteins (Cry) (Schnepf et al., 1998; Ellis
et al., 2002)
Event MIR604 expresses a modified
version of the native Cry3A protein
(Chen and Stacy, 2003). mCry3A is a
protein toxic to certain coleopteran
larvae feeding on maize
PMI(a) Based on a gene from E. coli. PMI
(phosphomannose isomerase) catalyses the
isomerisation of mannose-6-phosphate to
fructose-6-phosphate and plays a role in the
metabolism of mannose (Markovitz et al.,
1967)
Event MIR604 expresses PMI, which
is used as selectable marker. Mannose
normally inhibits root growth,
respiration and germination.
Transformed cells expressing PMI are
able to utilise mannose as a carbon
source (Negrotto et al., 2000)
1507 Cry1F Based on genes from Bacillus thuringiensis
subsp. aizawai. B. thuringiensis is an insect
pathogen; its insecticidal activity is attributed
to the expression of crystal protein (Cry)
(Schnepf et al., 1998; Ellis et al., 2002)
Event 1507 expresses a truncated
version of the Cry1F protein. Cry1F is
a protein toxic to certain lepidopteran
larvae feeding on maize
PAT Based on a gene from Streptomyces
viridochromogenes T€u494. Phosphinothricin-
acetyl-transferase (PAT) enzyme acetylates L-
glufosinate-ammonium (Thompson et al.,
1987; Wohlleben et al., 1988; Eckes et al.,
1989)
Event 1507 expresses the PAT protein
which confers tolerance to glufosinate
ammonium-based herbicides (Droge-
Laser et al., 1994)
5307 eCry3.1A Based on genes from Bacillus thuringiensis
subsp. kurstaki and subsp. tenebrionis.
B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the
expression of crystal protein (Cry) (Schnepf
et al., 1998; Ellis et al., 2002)
Event 5307 expresses the synthetic
protein eCry3.1Ab which is a chimera
composed of the N-terminal portion
of the mCry3A and the C-terminal
portion of the Cry1Ab protein.
eCry3.1Ab is an insecticidal protein
toxic to certain coleopteran larvae
feeding on maize
PMI(a) Based on a gene from E. coli.
Phosphomannose isomerase (PMI) catalyses
the isomerisation of mannose-6-phosphate to
fructose-6-phosphate and plays a role in the
metabolism of mannose (Markovitz et al.,
1967)
Event 5307 expresses PMI, which is
used as selectable marker. Mannose
normally inhibits root growth,
respiration and germination.
Transformed cells expressing PMI are
able to utilise mannose as a carbon
source (Negrotto et al., 2000)
GA21 mEPSPS Based on a gene from Zea mays. 5-
enolpyruvylshikimate-3-phosphate synthase
(EPSPS) is an enzyme involved in the shikimic
acid pathway for aromatic amino acid
biosynthesis in plants and microorganisms
(Herrmann, 1995)
Event GA21 expresses mEPSPS
protein which is a modified version of
the endogenous EPSPS enzyme that
confers tolerance to glyphosate-based
herbicides (Lebrun et al., 2003)
(a): It includes the PMI expressed in MIR162 and 5307 and that expressed in MIR604. These two PMI variants differ by two
amino acids.
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3.3.1.2. Integrity of the events in maize Bt11 3 MIR162 3 MIR604 3 1507 3 5307 3
GA21
The genetic stability of the inserted DNA over multiple generations in the single maize events Bt11,
MIR162, MIR604, 1507, 5307 and GA21 was previously demonstrated (see Table 2). Integrity of these
events in the six-event stack maize was demonstrated by Southern analyses.
3.3.1.3. Information on the expression of the inserts
Cry1Ab, PAT, Vip3Aa20, PMI, mCry3A, Cry1F, eCry3.1Ab and mEPSPS protein levels were analysed by
enzyme-linked immunosorbent assay (ELISA) in material harvested from a field trial across three
locations in the USA in 2012. Samples analysed included leaf (stage V6 and R1), root (V6 and R1), whole
plant (V6 and R1), pollen (R1) and grain (R6 and senescence) not treated with intended herbicides.
In order to assess changes in protein expression levels which may result from potential interactions
between the events, protein levels were determined for the six-event stack maize and the corresponding
single events in different parts of the plant.
The levels of the proteins newly expressed in the six-event stack and the corresponding singles
were comparable in all tissues except for PAT and PMI, which showed the expected higher levels in the
stack resulting from the combination of events Bt11 and 1507 (producing PAT) and the combination of
events MIR162, 5307 and MIR604 (producing PMI) respectively (Appendix A). The mEPSPS expression
levels measured for some of the analysed tissues were low (most samples were below the limit of
quantification (LOQ)) and therefore quantitative data for mEPSPS in those tissues were derived from a
limited number of samples. Based on the available data, there is no indication of interactions that may
affect the levels of the newly expressed proteins in this stack.
3.3.1.4. Conclusions of the molecular characterisation
The molecular data establish that the events stacked in the six-event stack maize have retained
their integrity. Protein expression analyses show that the levels of the newly expressed proteins are
similar in the six-event stack maize and the single events except for the expected higher levels of PAT
and PMI. Therefore, there is no indication of an interaction that may affect the levels of the newly
expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins, the only foreseen
interactions at the biological level are between the Vip3Aa20 protein and the Cry proteins and between
the Cry proteins in susceptible insects, which is dealt with in Section 3.3.4.4.
3.3.2. Comparative analysis7
3.3.2.1. Choice of comparator and production of material for the comparative assessment
Application EFSA-GMO-DE-2011-103 presents data on agronomic and phenotypic characteristics and
on forage and grain composition of the six-event stack maize derived from field trials performed in the
USA in 2012 (Table 5).
The field trials were conducted in major maize-growing areas of the USA, representing regions of
diverse agronomic practices and environmental conditions. All the materials were treated with plant
protection products (PPP) according to local requirements. At each site, the following materials were
grown in a randomised complete block design with four replications: the six-event stack maize not
Table 5: Overview of comparative analysis studies with maize Bt11 9 MIR162 9 MIR604 9
1507 9 5307 9 GA21 provided in application EFSA-GMO-NL-2013-103
Study focus Study details Comparator
Commercial non-GM
reference varieties
Agronomic and phenotypic
characteristics and
compositional analysis
Field trial study, 2012, USA,
eight sites(a)
5XH751 9 NP2222 Six(b)
(a): The field sites were located in: Atlantic, Richland and Bagley in Iowa; Seymour and Wyoming in Illinois; York in Nebraska;
Delavan in Wisconsin and Larned in Kansas.
(b): H-6044, NK SYMBA, NK THERMO, X36344, H-7191 and H-7540. All six non-GM maize hybrids were grown at every location.
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treated with the intended herbicides, the six-event stack maize treated with glyphosate- and glufosinate-
ammonium-containing herbicides, a non-GM comparator and six non-GM maize reference varieties. The
six-event stack maize was obtained by conventional crossing of the six single events. Events Bt11,
MIR162, MIR604, 5307 and GA21 were introgressed via backcrossing in the inbred line NP2222, while
event 1507 in 5XH751. As documented by the pedigree, the six single events, after backcrossing, were
combined in a hybrid maize with genetic background (F1) 5XH751 9 NP2222. The same two inbred lines
(5XH751 and NP2222) were crossed to produce the non-GM hybrid maize used as comparator
(5XH751 9 NP2222). The GMO Panel considered the selected non-GM comparator suitable.
The GMO Panel noted that the comparative relative maturity of the selected non-GM reference
varieties was shorter than the optimal range for the chosen sites. However, the GMO Panel considered
that at most of the field trial sites sowing occurred relatively late, close to the limit of the typical range.
Therefore, considering the specific conditions under which the materials were grown and in light of the
typical range of growing conditions in USA, the non-GM reference varieties are considered acceptable.
The seeds of the six-event stack hybrid maize and of its non-GM comparator that were sown to
conduct the comparative assessment studies were produced under similar conditions. The seeds were
also tested for their quality and germinability and were considered by the GMO Panel to be of
adequate quality.
Statistical analysis of field trial data
The statistical analysis of the agronomic, phenotypic and compositional data from the field trials
followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010e, 2011a). This includes, for
each of the two treatments of the six-event stack maize, the application of a difference test (between
the GM maize and the non-GM comparator) and an equivalence test (between the GM maize and the
set of non-GM commercial reference varieties). The results of the equivalence test are categorised into
four possible outcomes (I–IV, ranging from equivalence to non-equivalence).8
3.3.2.2. Agronomic and phenotypic characterisation
Fourteen traits related to crop physiology, morphology, development and yield were measured.9 Of
those, five were not analysed as described in Section 3.3.2.1 because of high discreteness and lack of
variability in the data.10
The outcome of the analysis for the remaining nine endpoints was as follows:
• For the six-event stack maize (not treated with the intended herbicides), statistically significant
differences with the non-GM comparator were identified for early stand count, final stand count,
days to 50% pollen shed and days to 50% silking. All these endpoints fell under equivalence
category I or II, except for early and final stand count which fell under equivalence category IV.11
Grain moisture fell under equivalence category IV; however, no significant differences were
identified with the non-GM comparator.
• For the six-event stack maize (treated with the intended herbicides), statistically significant
differences with the non-GM comparator were identified for early stand count, final stand count,
days to 50% pollen shed, days to 50% silking, ear height and grain moisture. All these
endpoints fell under equivalence category I or II, except for early stand count, final stand count,
days to 50% pollen shed and grain moisture, which fell under equivalence category III or IV.12
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8 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
9 The traits were: early stand count, final stand count, early growth rating (seedling vigour), days to 50% pollen shed, days to
50% silking, ear height, plant height, stalk lodged plants, root lodged plants, stay green, dropped ears, grain yield, grain
moisture and test weight.
10 Early growth rating, stay green, root lodged plants, stalk lodged plants and dropped ears.
11 Estimated means for early stand count: 62.1 (untreated GM maize), 59.1 (treated GM maize), 75.8 (non-GM comparator) and
76.5 (non-GM reference varieties); equivalence limits: (71.3, 81.7). Estimated means for final stand count: 60.8 (untreated GM
maize), 58.0 (treated GM maize), 72.7 (non-GM comparator) and 72.8 (non-GM reference varieties); equivalence limits: (67.5,
78.1).
12 Estimated means for days to 50% pollen shed: 57.8 (untreated GM maize), 58.1 (treated GM maize), 56.5 (non-GM
comparator) and 54.1 (non-GM reference varieties); equivalence limits: (50.4, 57.8). Estimated means for grain moisture (%):
17.5 (untreated GM maize), 17.2 (treated GM maize), 18.1 (non-GM comparator) and 14.9 (non-GM reference varieties);
equivalence limits: (13.1, 16.7).
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For days to 50% pollen shed and grain moisture, the estimated mean values for the GM maize and
the non-GM comparator are higher than those for the non-GM reference varieties. The GMO
Panel considers that these results are linked to the relatively short cycle of the selected non-GM
reference lines (see Section 3.3.2.1). Although it is not clear why early and final stand count were
reduced, the GMO Panel considers that these differences do not affect the use of the field trial data for
the comparative analysis, as no changes were observed for the other yield components (yield and test
weight). Whether the differences identified can lead to an environmental adverse effect is considered
in Section 3.3.4.
Additionally, no altered stress responses of the six-event stack maize were observed compared with
its non-GM comparator with regard to visually observable responses to naturally occurring diseases,
arthropod damage and abiotic stressors.
3.3.2.3. Compositional analysis
Maize forage and grains harvested from the field trial study in the USA in 2012 were analysed for
82 constituents (9 in forage and 73 in grain), including the key constituents recommended by OECD
(OECD, 2002). The statistical analysis was not applied to 17 grain constituents13 because more than
half of the observations were below the limit of quantification. Moisture level was also not analysed, as
the values reported do not refer to the moisture content of the grains at the time of harvesting but to
the content following mechanical drying of the grains in the field before the laboratory analysis.
The statistical analysis was applied to the remaining 64 constituents (9 in forage14 and 55 in grain15);
a summary of the outcome of the test of difference and the test of equivalence is presented in Table 6.
• For the six-event stack maize (not treated with the intended herbicides), significant differences
with the non-GM comparator were identified for 25 endpoints (2 in forage and 23 in grain); of
those, six grain endpoints fell under equivalence category III/IV (ash, b-carotene, ferulic acid,
potassium, zinc and methionine) while the other endpoints fell under category I/II. Six more
endpoints fell under equivalence category III/IV (Table 6); for those, however, no significant
differences with the non-GM comparator were identified.
• For the six-event stack maize (treated with the intended herbicides), significant differences
with the non-GM comparator were identified for 24 endpoints (1 in forage and 23 in grain); of
those, eight grain endpoints fell under equivalence category III/IV (ash, b-carotene, folic acid,
ferulic acid, potassium, zinc, arachidic acid (C20:0) and methionine) while the other endpoints
fell under category I/II. Four more endpoints fell under equivalence category III/IV (Table 6);
for those, however, no significant differences with the non-GM comparator were identified.
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13 Caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), myristic acid (C14:0), myristoleic acid (C14:1), pentadecanoic
acid (C15:0), pentadecenoic acid (C15:1), heptadecanoic acid (C17:0), heptadecenoic acid (C17:1), c-linolenic acid (C18:3),
eicosadienoic acid (C20:2), eicosatrienoic acid (C20:3), arachidonic acid (C20:4), selenium, sodium, furfural and raffinose.
14 Moisture, protein, fat, ash, carbohydrates, acid detergent fibre (ADF), neutral detergent fibre (NDF), calcium and phosphorus.
15 Proximates and fibre content (protein, fat, ash, carbohydrates, acid detergent fibre (ADF), neutral detergent fibre (NDF) and
total detergent fibre (TDF)), starch, minerals (calcium, copper, iron, magnesium, manganese, phosphorus, potassium and
zinc), vitamins (b-carotene, thiamine, riboflavin, niacin, pyridoxine, folic acid and a-tocopherol), amino acids (alanine, arginine,
aspartic acid, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine,
threonine, tryptophan, tyrosine and valine), fatty acids (palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0),
oleic acid (C18:1), linoleic acid (C18:2), linolenic acid (C18:3), arachidic acid (C20:0), eicosenoic acid (C20:1) and behenic acid
(C22:0)) and other compounds (ferulic acid, inositol, p-coumaric acid, phytic acid and trypsin inhibitor).
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The GMO Panel assessed all significant differences between the six-event stack maize and its non-
GM comparator, taking into account the potential impact on plant metabolism and the natural
variability observed for the set of non-GM maize reference varieties. Quantitative results for the
endpoints showing significant differences between the six-event stack maize and its non-GM
comparator and falling under equivalence category III/IV are given in Table 7.
Table 6: Outcome of the comparative compositional analysis of grains and forage from maize
Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21. The table shows the number of
endpoints in each category
Test of difference(b)
Not treated(c) Treated
Not
different
Significantly
different
Not
different
Significantly
different
Test of
equivalence(b)
Category I/II 32 19(d) 35 16(d)
Category III/IV 6(e) 6(f) 4(e) 8(f)
Not categorised 1(g) –(h) 1(g) –(h)
Total endpoints 64 64
(a): Comparison between the six-event stack maize and the non-GM comparator.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated with intended herbicides glyphosate and glufosinate-ammonium.
(d): Endpoints with significant differences between the six-event stack maize and its non-GM comparator and falling in
equivalence category I/II. For grains, for both treated and non-treated GM: NDF, manganese, phosphorus, glycine,
threonine, oleic acid (C18:1), linoleic acid (C18:2), phytic acid and pyridoxine. Only non-treated: fat, iron, arginine, cystine,
palmitoleic acid (C16:1), linolenic acid (C18:3), inositol and riboflavin. Only treated: protein, ADF, glutamic acid, proline,
serine and behenic acid (C22:0). For forage, for both treated and non-treated GM: moisture. Non-treated only: phosphorus.
(e): Endpoints with no significant differences between the six-event stack maize and its non-GM comparator and falling in
equivalence category III/IV. For grains, for both treated and non-treated GM: TDF, stearic acid (18:0) and thiamine. Only
non-treated: arachidic acid (C20:0) and folic acid. For forage, for both treated and non-treated GM: protein.
(f): Endpoints with significant differences between the six-event stack maize and its non-GM comparator and falling in
equivalence category III/IV. Quantitative results are reported in Table 7.
(g): Endpoints not categorised for equivalence and without significant differences between the six-event stack maize and its non-
GM comparator: trypsin inhibitor in grain (both treated and not treated).
(h): Endpoints not categorised for equivalence and with significant differences between the six-event stack maize and its non-GM
comparator: none.
Table 7: Quantitative results (estimated means and equivalence limits) for compositional endpoints
in grain that are further assessed based on the results of the statistical analysis
Endpoint
Maize Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
Non-GM
comparator
5XH751 3
NP2222
Non-GM reference varieties
Non-treated Treated(a) Mean Equivalence limits
Ash (% dw) 1.45* 1.47* 1.34 1.34 1.25–1.44
Potassium (mg/kg dw) 4,070* 4,100* 3,670 3,470 3,110–3,850
Zinc (mg/kg dw) 18.0* 18.3* 20.3(b) 24.7 21.2–29.0
b-Carotene (mg/100 g dw) 0.073* 0.076* 0.086 0.132 0.077–0.224
Folic acid (mg/100 g dw) 0.051 0.055* 0.049(b) 0.040 0.036–0.045
Methionine (mg/g dw) 1.99* 1.98* 2.10(b) 2.29 2.12–2.48
Arachidic acid (C20:0) (% FA) 0.48 0.48* 0.47 0.43 0.38–0.48
Ferulic acid (mg/kg dw) 2,970* 2,970* 2,750 2,230 1,790–2,780
dw: dry weight; FA: total fatty acid.
(a): Treated with the intended herbicides glyphosate and glufosinate-ammonium.
(b): For folic acid, zinc and methionine, the mean value of the non-GM comparator was out of the equivalence limits derived
from the non-GM commercial reference varieties.
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3.3.2.4. Conclusions of the comparative analysis
Taking into account the natural variability observed for the set of non-GM reference varieties, the
GMO Panel concludes that:
• None of the differences identified in the agronomic and phenotypic characteristics tested
between the six-event stack maize and the non-GM comparator needs further assessment,
except for the changes in early stand count, final stand count, days to 50% pollen shed and
grain moisture. These differences are further assessed for their potential environmental impact
in Section 3.3.4.
• None of the differences identified in forage and grain composition between the six-event stack
maize and the non-GM comparator needs further food/feed safety assessment except for the
changes in levels of ash, potassium, zinc, b-carotene, folic acid, methionine, arachidic acid and
ferulic acid. These differences are further discussed in Section 3.3.3.
3.3.3. Food and feed safety assessment16
3.3.3.1. Effects of processing
The six-event stack maize will undergo existing production processes used for conventional maize.
Considering the changes observed in the compositional comparative analysis (Section 3.3.2.3), the
processing of the six-event stack maize into food and feed products is not expected to result in
products being different from those from conventional non-GM maize varieties.
3.3.3.2. Influence of temperature and pH on newly expressed proteins
The effects of temperature and pH on the newly expressed proteins in this six-event stack maize
have been previously evaluated by the GMO Panel (Table 2). No new information has been provided in
the context of this application.
3.3.3.3. Toxicology
Testing of newly expressed proteins
Eight proteins (Cry1Ab, Vip3Aa20, mCry3A, Cry1F, eCry3.1Ab, PAT, PMI17 and mEPSPS) are newly
expressed in the six-event stack maize (Section 3.3.1). The GMO Panel has previously assessed these
proteins in the context of the single maize events (Table 2) and no safety concerns were identified for
humans and animals. The GMO Panel is not aware of any new information that would change these
conclusions.
The potential for a functional interaction between the proteins newly expressed in this six-event
stack maize has been assessed with regard to human and animal health. The insecticidal proteins
Cry1Ab, mCry3A, Cry1F and eCry3.1Ab are delta-endotoxins acting through cellular receptors found in
target insect species. It is reported that the gastrointestinal tract of mammals, including humans, lacks
receptors with high-specific affinity to Cry proteins (Hammond et al., 2013; Koch et al., 2015). The
Vip3Aa20 protein is a protein secreted by B. thuringiensis during its vegetative phase acting in target
insects via a mechanism similar to that of Cry proteins (Bel et al., 2017; Chakroun et al., 2016). The
PAT, PMI and mEPSPS proteins are enzymes that catalyse distinct biochemical reactions and act on
unrelated substrates with high substrate specificity.
On the basis of the known biological functions of the individual newly expressed proteins (Table 4),
there is currently no expectation for possible interactions relevant to the food and feed safety of the
six-event stack maize.
The expression levels of the newly expressed proteins in the six-event stack maize were similar to
those of the single events with the exception of PMI and PAT (Section 3.3.1). Total levels of these
newly expressed proteins were consistently higher in the tissues of the six-event stack maize than in
For the six-event stack maize, significantly different values are marked with an asterisk, while the outcomes of the test of
equivalence are differentiated by greyscale backgrounds: white (equivalence category I or II), light grey (equivalence category III)
and dark grey (equivalence category IV).
For all endpoints, the analysis was done on a logarithmic scale, and the results were transformed back to the original scale.
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those of the individual events. This could be expected, given the introduction of multiple copies of the
respective genes. Introduction of PMI activity in the single events did not result in changes of relevant
endogenous compounds (i.e. sugars, sugar alcohols and sugar phosphates) compared with the
conventional counterparts (Table 2). There is no expectation that this enzyme would also have impact
on carbohydrate metabolism in the six-event stack maize.
In vitro protein degradation studies on Cry1Ab, Vip3Aa20, mCry3A, Cry1F, eCry3.1Ab, PAT, PMI17
and mEPSPS proteins have been previously evaluated by the GMO Panel (Table 2). In the context of
this application, no new studies addressing in vitro protein degradation of these newly expressed
proteins were provided by the applicant.
The GMO Panel concludes that there are no safety concerns to human and animal health related to
the newly expressed proteins Cry1Ab, Vip3Aa20, mCry3A, Cry1F, eCry3.1Ab, PAT, PMI and mEPSPS in
maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21.
Testing of new constituents other than proteins
No new constituents other than the newly expressed proteins have been identified in the six-event
stack maize. Therefore, no further food and feed safety assessment of components other than the
newly expressed proteins is required.
Information on altered levels of food and feed constituents
The levels of ash, potassium, zinc, b-carotene, folic acid, methionine, arachidic acid (C20:0) and
ferulic acid in grains from the six-event stack maize were significantly different from its non-GM
comparator and showed a lack of equivalence with the set of non-GM commercial reference varieties
(Section 3.3.2.3). Taking into account the biological characteristics and functions of these compounds,
the observed differences are considered of no toxicological concern by the GMO Panel. Further
information on the safety of these maize constituents is provided in Section 3.3.3.5.
Testing of the whole genetically modified food and feed
No animal studies with the food/feed derived from the six-event stack maize were provided. Based
on the outcome of the studies considered in the molecular characterisation and comparative analysis,
no substantial modifications of toxicological concern in the composition of the six-event stack maize,
and no indication of possible unintended effects relevant to food/feed safety have been identified (see
Sections 3.3.1 and 3.3.2.3). Therefore, animal studies on food/feed derived from the six-event stack
maize are not necessary (EFSA GMO Panel, 2011a).
3.3.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all of the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufficient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a). In addition, when known functional aspects of the newly expressed protein or
structural similarity to known adjuvants may indicate an adjuvant activity, the possible role of these
proteins as adjuvants is considered. When newly expressed proteins with a potential adjuvant activity
are expressed together, possible interactions increasing adjuvanticity and impacting the allergenicity of
the GM crop are assessed.
Assessment of allergenicity of the newly expressed proteins
For allergenicity, the GMO Panel has previously evaluated the safety of Cry1Ab, PAT, Vip3Aa20,
PMI,17 mCry3A, Cry1F, eCry3.1Ab and mEPSPS proteins individually, and no concerns on allergenicity
were identified in the context of the applications assessed (see Table 2). No new information on
allergenicity of these proteins that might change the previous conclusions of the GMO Panel has
become available. Based on the current knowledge, and as none of the newly expressed proteins
showed allergenicity, no reasons for concerns regarding the simultaneous presence of these newly
expressed proteins in the six-event stack maize affecting their allergenicity are expected.
For adjuvanticity, the Bt protein Cry1Ac has been suggested to possess adjuvant activity based on
animal studies when applied at relatively high doses (e.g. Vazquez et al., 1999). The Panel has
previously evaluated the safety of Cry1Ab, Vip3Aa20, mCry3A, Cry1F and eCry3.1Ab proteins, and no
concerns on adjuvanticity were identified in the context of the applications assessed (see Table 2). The
levels of the individual Bt proteins in the six-event stack maize are similar to those in the respective
single maize events (see Section 3.3.1.3). From the limited evidence available, the GMO Panel does
Assessment of maize Bt11 3 MIR162 3 MIR604 3 1507 3 5307 3 GA21 and subcombinations
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2019;17(4):5635
not find indications that the presence of the Bt proteins at the levels expressed in the six-event stack
maize might act as adjuvants with the potential to enhance a specific immunoglobulin E (IgE) response
and to favour the development of an allergic reaction.
Assessment of allergenicity of GM plant products
The GMO Panel regularly reviews the available publications on food allergy to maize. However,
maize is not considered a common allergenic food18 (OECD, 2002). Therefore, the GMO Panel does not
request experimental data to analyse the allergen repertoire of GM maize.
The applicant provided spontaneous information where levels of lipid transfer protein (LTP, a known
allergen also present in maize) in the six-event stack maize were compared to those in a non-GM
comparator and commercial reference varieties. No changes in expression levels raising concern were
identified.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see Sections 3.3.1, 3.3.2
and 3.3.3.3), the GMO Panel identifies no indications of a potentially increased allergenicity of food and
feed derived from the six-event stack maize with respect to those derived from its non-GM comparator.
3.3.3.5. Nutritional assessment of GM food/feed
The intended trait of the six-event stack maize is insect resistance and herbicide tolerance, with no
intention to alter the nutritional parameters. However, the levels of ash, potassium, zinc, b-carotene,
folic acid, methionine, arachidic acid (C20:0) and ferulic acid in grains from the six-event stack maize
were significantly different from the non-GM comparator and showed a lack of equivalence with the
set of non-GM commercial reference varieties (Section 3.3.2.3). The biological roles of these
compounds, the contribution of maize to their total intake and the magnitude and direction of the
observed changes are considered in the nutritional assessment.
Human nutrition
Statistically significant differences were identified for potassium and zinc. Regarding potassium, no
tolerable upper intake level (UL) exists, therefore the observed increase of around 10% is considered
irrelevant from a nutritional point of view. Zinc is an essential mineral in the diet, being an important
part of the structure of certain proteins and serving as a cofactor for many enzymes. The main dietary
sources of zinc are foods of animal origin, particularly meat, milk and their derived products (EFSA
NDA Panel, 2014). Although cereals are also considered relevant contributors to the total intake of zinc
in the diet, it is widely recognised that mineral bioavailability is substantially decreased due to the
presence of phytic acid (Suri and Tanumihardjo, 2016). The quantity of dietary zinc available for
absorption strongly depends on overall dietary levels of phytate intake (EFSA NDA Panel, 2014).
Therefore, the decrease of approximately 10% of zinc levels is not considered relevant. The increased
levels of ash in the GM-maize are probably explained by the higher levels of salts of potassium, the
most abundant mineral in maize.
b-Carotene is a precursor of vitamin A and is found in plant derived foods; together with preformed
vitamin A (mainly retinol and retinyl esters) present in foods of animal origin it contributes to the total
dietary intake of vitamin A. Milk, meat, vegetables and derived products are the main sources of
vitamin A in the diet. Cereals and cereal-based products contribute much less to the total intake of
vitamin A, with contributions in the adult population ranging between 2.7% and 6.5% of the total
(average contribution = 4.1%), with the maximum contribution (10%) estimated in adolescents (EFSA
NDA Panel, 2015). The decrease observed in b-carotene is not considered relevant from a nutritional
point of view. An increase of up to 12% of folic acid (folate, the natural form present in food) was
observed in the six-event stack maize as compared to the non-GM comparator. Green vegetables and
certain (citrus) fruits are important dietary sources of folates. Although UL are set for folic acid, the
relatively high upper limits (200–1,000 lg/day19) as compared to the levels present in maize
(~ 0.005 mg/100 g dw) make the observed changes irrelevant from a nutritional point of view.
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Methionine is an essential amino acid containing sulfur; maize possesses an amino acid pattern that
covers 132% of the sulfur amino acid (SAA) pattern requirements; therefore, the nutritional impact of
the observed decrease (~6%) is considered negligible. An increase of arachidic acid (C20:0) levels was
observed in the six-event stack maize; however, considering the minor relative amount of this fatty
acid in maize (less than 0.5% of total FA) and the negligible contribution of maize to its dietary intake
as compared to other dietary sources (e.g. peanut oil), the slight increase is not nutritionally relevant.
Ferulic acid (4-hydroxy-3-methoxycinnamic) is the most abundant phenolic compound in maize grain
(Boz, 2015; Bento-Silva et al., 2018). Maize is one of the most important dietary sources of ferulic acid
in humans. No toxicity has been linked to the dietary intake of ferulic acid, being a phenolic compound
easily absorbed and metabolised in humans. Therefore, the observed increase in the six-event stack
maize is not considered nutritionally relevant.
Animal nutrition
Ash is a component of the proximates and provides a measure of the total amount of minerals
present in feed, without offering a qualitative and quantitative insight for specific minerals. Moreover,
animal requirements for ash are not provided. Therefore, the nutritional impact of the increase (~8%)
is considered negligible. Potassium and zinc are essential minerals naturally occurring in feed material
(e.g. plant and plant products), of importance for their physiological function in the metabolism of
animals. Animal diets are usually balanced with mineral supplements according to the foreseen uses,
therefore the observed changes are not considered nutritionally relevant and do not pose a risk for
animals. Considering that the significance of b-carotene in diets for animals is negligible because these
are supplemented with vitamin A, the observed lower level would not affect its total dietary intake in
the European animal population. Folic acid, rarely analysed in animal feed, is widely distributed in
nature (e.g. green leafy materials, cereals) and it is synthesised by microbes in the rumen.
Underfeeding of this acid should be avoided because it has an important role in the metabolism,
especially during pregnancy, for RNA and DNA synthesis of fetal and placental tissues. The direction
and magnitude of the change observed do not pose a concern for animal nutrition. Methionine is an
essential amino acid for all animals; however, the nutritional impact of the observed decrease (~6%)
can be considered negligible, and diets are also balanced with synthetic amino acids, as needed.
Arachidic acid is a saturated fatty acid structurally related to arachidonic acid. The magnitude of the
increase of arachidic acid content is considered negligible with no nutritional impact for animals, also
considering the minor amount of this fatty acid in maize. Ferulic acid is not considered a major
element in animal nutrition. Among whole grain cereals, maize has the highest content in ferulic acid,
but other sources of ferulic acid in animal nutrition are normally used, such as grain brans and sugar
beet pulp. The magnitude of the change observed does not pose a concern for animal nutrition.
Conclusion on human and animal nutrition
Based on the current knowledge of the biological role of the compounds assessed, the magnitude
and direction of the changes identified, and the relevance of maize as contributor to the intake of
these compounds, the GMO Panel concludes that the nutritional impact of foods and feeds from the
six-event stack maize is expected to be the same as that of foods and feeds derived from the
comparator and non-GM reference varieties.
3.3.3.6. Conclusion of the food and feed safety assessment
The proteins Cry1Ab, PAT, Vip3Aa20, PMI, mCry3A, Cry1F, eCry3.1Ab and mEPSPS newly expressed
in the six-event stack maize do not raise safety concerns for human and animal health. Interactions
between these newly expressed proteins raising food and feed safety concerns (toxicological,
allergenicity and adjuvanticity) are not expected. The nutritional impact of the six-event stack maize
foods and feeds is expected to be the same as those from the comparator and non-GM reference
varieties. The GMO Panel concludes that the six-event stack maize, as described in this application, is
as safe as and nutritionally equivalent to the comparator and the non-GM reference varieties tested.
3.3.4. Environmental risk assessment20
Considering the scope of application EFSA-GMO-DE-2011-103, which excludes cultivation, the
environmental risk assessment (ERA) of maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21
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mainly takes into account: (1) the exposure of microorganisms to recombinant DNA in the
gastrointestinal tract of animals fed GM material and of microorganisms present in environments
exposed to faecal material of these animals (manure and faeces); and (2) the accidental release into the
environment of viable six-event stack maize grains during transportation and/or processing (EFSA GMO
Panel, 2010a).
3.3.4.1. Persistence and invasiveness of the GM plant
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, absence of a dormancy phase and susceptibility to plant
pathogens, herbivores and cold climate conditions (OECD, 2002). Field observations indicate that maize
grains may survive and overwinter in some EU regions, resulting in volunteers in subsequent crops (e.g.
Gruber et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers have been
shown to grow weakly and flower asynchronously with the maize crop (Palaudelmas et al., 2009). Thus,
the establishment and survival of feral and volunteer maize in the EU is currently limited and transient.
It is unlikely that the intended traits of the six-event stack maize and the observed decreased in
early stand count, final stand count, days to 50% pollen shed and grain moisture (see Section 3.3.2.2)
will provide a selective advantage to maize plants, except when they are exposed to glyphosate- and/or
glufosinate-ammonium-containing herbicides or infested by insect pests that are susceptible to the Bt
proteins expressed by this GM maize. However, this fitness advantage will not allow the six-event stack
maize to overcome other biological and abiotic factors (described above) limiting plant’s persistence and
invasiveness. Therefore, the presence of the intended traits and the observed differences in early stand
count, final stand count, days to 50% pollen shed and grain moisture will not affect the persistence and
invasiveness of the GM plant.
In conclusion, the GMO Panel considers it is very unlikely that the six-event stack maize will differ
from conventional maize hybrid varieties in its ability to survive until subsequent seasons, or to
establish occasional feral plants under European environmental conditions in case of accidental release
into the environment of viable six-event stack maize grains.
3.3.4.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either HGT of DNA, or through vertical gene flow via cross-pollination from feral plants
originating from spilled grains.
Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in previous GMO Panel Scientific Opinions for the single events (see Table 2). No concern as a result of
an unlikely, but theoretically possible, horizontal gene transfer of the recombinant genes to bacteria in
the gut of domesticated animals and humans fed GM material or other receiving environments was
identified. The applicant submitted an updated bioinformatic analysis for each of the single events in
order to assess the possibility for HGT by homologous recombination.
The updated bioinformatics analysis for maize event Bt11 revealed elements that are intervening
sequences flanking the cry1Ab expression cassette. These could provide sufficient length and sequence
identity to plasmid bacterial DNA, as typically present in bacterial cloning vectors, to allow double
homologous recombination. The analysis revealed a number of possible recipient organisms including
E. coli; however, the size of the non-homologous insert is relatively extensive (> 3100 bp), which
decreases recombination efficiency (EFSA, 2017b). The cry1Ab is of bacterial origin and it is plant
codon-optimised and under the control of plant virus elements and thus unlikely to be functional in
bacteria. The analysis also identified a ~ 250 bp-long DNA sequence of sufficient identity to a single
site on an A. tumefaciens nopaline Ti plasmid. This would not increase the potential for facilitated HGT
by double homologous recombination.
The bioinformatic analyses of maize events MIR162, MIR604 and 5307 revealed similar results. In
all three events, the pmi gene derived from E. coli and the T-nos terminator of an A. tumefaciens
nopaline plasmid were identified as elements with sufficient length and sequence identity to facilitate
homologous recombination. Considering that these sequences do not occur in the same bacterial
species, there is no indication for facilitated double homologous recombination for these three events.
Assessment of maize Bt11 3 MIR162 3 MIR604 3 1507 3 5307 3 GA21 and subcombinations
www.efsa.europa.eu/efsajournal 21 EFSA Journal 2019;17(4):5635
The bioinformatic analysis of maize event GA21 identified a ~250 bp-long DNA sequence, present in
three copies in the event, of sufficient identity to a single site on an A. tumefaciens nopaline Ti plasmid.
Because of the lack of a second site with sequence identity, no increased potential for facilitated HGT by
double homologous recombination was identified.
The updated bioinformatic analysis provided in this application for maize event 1507 confirms the
assessments provided in the context of previous applications (EFSA GMO Panel, 2019a,b).
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for horizontal gene transfer or a selective
advantage are not identified.
Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal transfer
of recombinant genes from this six-event stack maize to bacteria does not raise any environmental
safety concern.
Plant-to plant-gene transfer
The GMO Panel assessed the potential for occasional feral six-event stack maize plants originating
from grain import spills to transfer recombinant DNA to sexually compatible plants; the environmental
consequences of this transfer were also considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
flowering and environmental conditions favouring cross-pollination.
Maize is an annual predominantly cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize outside
cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA, 2016;
Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and weedy Zea
species, such as teosintes and/or maize-teosinte hybrids, occurring in cultivated areas (EFSA, 2016;
Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.3.4.1). Therefore, likelihood/frequency of cross-pollination between occasional
feral GM maize plants resulting from grain spillage, and weedy or cultivated Zea plants is considered
extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the opinion that
environmental effects as a consequence of the spread of genes from occasional feral GM maize plants
in Europe will not differ from that of conventional maize varieties for the reasons given in
Section 3.3.4.1, even if exposed to the intended herbicides.
3.3.4.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-DE-2011-103 into account (no cultivation), potential
interactions of occasional feral six-event stack maize plants arising from grain import spills with target
organisms are not considered a relevant issue by the GMO Panel.
3.3.4.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled six-event stack maize grains is limited, and because ingested
proteins are degraded before entering the environment through faecal material of animals fed GM
maize, potential interactions of the six-event stack maize with non-target organisms are not considered
by the GMO Panel to raise any environmental safety concern. Interactions that may occur between the
Cry proteins would not alter this conclusion.
3.3.4.5. Interactions with the abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled grains or occasional feral six-event stack maize plants
arising from grain import spills is limited, and because most proteins are degraded before entering the
environment through faecal material of animals fed GM maize, potential interactions with the abiotic
environment and biogeochemical cycles are not considered to raise any environmental safety concern.
3.3.4.6. Conclusion of the environmental risk assessment
The GMO Panel concludes that it is unlikely that the six-event stack maize would differ from
conventional maize varieties in its ability to persist under EU environmental conditions. Considering the
scope of application EFSA-GMO-DE-2011-103, interactions of occasional feral six-event stack maize
plants with the biotic and abiotic environment are not considered to be relevant issues. The analysis of
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HGT from the six-event stack maize to bacteria does not indicate a safety concern. Therefore,
considering the combined traits, the outcome of the comparative analysis, and the routes and levels of
exposure, the GMO Panel concludes that the six-event stack maize would not raise safety concerns in
the event of accidental release of viable GM maize grains into the environment.
3.3.5. Conclusion on maize Bt11 3 MIR162 3 MIR604 3 1507 3 5307 3 GA21
No new data on the single maize events Bt11, MIR162, MIR604, 1507, 5307 and GA21 leading to a
modification of the original conclusions on their safety were identified.
The molecular characterisation, the comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single maize events and of the newly expressed proteins in the six-event
stack maize does not give rise to food and feed safety and nutritional concerns. The GMO
Panel concludes that the six-event stack maize, as described in this application, is as safe as and
nutritionally equivalent to its non-GM comparator and the non-GM reference varieties tested.
Considering the combined traits and their interactions, the outcome of the comparative analysis,
and routes and levels of exposure, the GMO Panel concludes that the six-event stack maize would not
raise safety concerns in the event of accidental release of viable GM maize grains into the
environment.
No scientific information that could change the conclusions on this six-event stack was retrieved in
a literature search covering the period since the time of validity of the application.21
In conclusion, the GMO Panel considers that the six-event stack maize is as safe as its non-GM
comparator and the tested non-GM maize reference varieties with respect to potential effects on
human and animal health and the environment.
3.4. Risk assessment of the subcombinations22
Subcombinations previously assessed in the frame of other applications are discussed in
Section 3.4.1.
The strategy followed for the assessment of those subcombinations which have not been previously
assessed has been described by the GMO Panel.23 In this case, the risk assessment takes as its
starting point the assessment of the single maize events, and uses the data generated for the six-
event stack, as well as all the additional data available on subcombinations previously assessed by the
GMO Panel (Table 2) and the new information on subcombinations not yet assessed.
3.4.1. Subcombinations previously assessed
The GMO Panel has previously assessed 22 subcombinations (10 two-event stacks, 9 three-event
stacks and 3 four-event stacks; see Table 2) and did not identify any safety concern. No new scientific
information relevant to the risk assessment of these maize stacks became available since the validation
of application EFSA-GMO-DE-2011-103. Consequently, the GMO Panel considers that its previous
conclusions on these subcombinations remain valid.
3.4.2. Subcombinations not previously assessed
Of the 56 subcombinations included in the scope of this application, 34 have not been assessed
previously by the GMO Panel (see Table 8).
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New information on three of these maize stacks became available since the validation of application
EFSA-GMO-DE-2011-103. The information is discussed in Sections 3.4.2.1–3.4.2.3.
3.4.2.1. Additional information on maize MIR604 3 5307 3 1507
Expression of the events
The applicant provided a study, not previously assessed by the GMO Panel, on protein expression
levels of the three-event stack MIR604 9 5307 9 1507 and the corresponding single events. The data
provided in this study are considered of limited value since they were derived from plants grown in
one location during one season. Therefore, these data are not representative and not in line with the
applicable GMO Panel guidelines (EFSA GMO Panel, 2011a). Hence, the GMO Panel has not taken
these data into account for the risk assessment.
Table 8: Subcombinations of maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 not
previously assessed and covered by the scope of application EFSA-GMO-DE-2011-103
Degree of Stacking Events
Five-event stack maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307
Bt11 9 MIR162 9 MIR604 9 1507 9 GA21
Bt11 9 MIR162 9 MIR604 9 5307 9 GA21
Bt11 9 MIR162 9 1507 9 5307 9 GA21
Bt11 9 MIR604 9 1507 9 5307 9 GA21(a)
MIR162 9 MIR604 9 1507 9 5307 9 GA21
Four-event stack maize Bt11 9 MIR162 9 MIR604 9 1507
Bt11 9 MIR162 9 MIR604 9 5307
Bt11 9 MIR604 9 1507 9 5307(a)
Bt11 9 MIR162 9 1507 9 5307
Bt11 9 MIR162 9 5307 9 GA21
Bt11 9 MIR604 9 5307 9 GA21
Bt11 9 1507 9 5307 9 GA21
MIR162 9 MIR604 9 1507 9 5307
MIR162 9 MIR604 9 1507 9 GA21
MIR162 9 MIR604 9 5307 9 GA21
MIR162 9 1507 9 5307 9 GA21
MIR604 9 1507 9 5307 9 GA21
Three-event stack maize Bt11 9 MIR162 9 5307
Bt11 9 MIR604 9 5307
Bt11 9 1507 9 5307
Bt11 9 5307 9 GA21
MIR162 9 MIR604 9 1507
MIR162 9 MIR604 9 5307
MIR162 9 1507 9 5307
MIR162 9 5307 9 GA21
MIR604 9 1507 9 5307(a)
MIR604 9 5307 9 GA21
1507 9 5307 9 GA21
Two-event stack maize Bt11 9 5307
MIR162 9 5307
MIR604 9 5307
1507 9 5307
5307 9 GA21
(a): Additional information was provided for this subcombination.
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Non-target organism risk assessment
The applicant provided a study assessing the risk of maize MIR604 9 5307 9 1507 to non-target
organisms. The GMO Panel considers this study not relevant because potential interactions of this
three-stacked event maize with non-target organisms are not relevant in the context of the scope of
application EFSA-GMO-DE-2011-103, which excludes cultivation.
3.4.2.2. Additional information on maize Bt11 3 MIR604 3 5307 3 1507
Insect resistance management plan
The applicant provided an insect resistance management plan for maize Bt11 9 MIR604 9 5307 9
1507 in Canada. The GMO Panel considers that this report does not contain any experimental data
and, therefore, it cannot be used to support the risk assessment of maize Bt11 9 MIR604 9
5307 9 1507.
3.4.2.3. Additional information on maize Bt11 3 MIR604 3 1507 3 5307 3 GA21
Integrity of the events
Two studies on the integrity of the events in the five-event stack maize Bt11 9 MIR604 9
1507 9 5307 9 GA21, not previously assessed by the GMO Panel, were submitted. The data
demonstrated integrity of these events in the five-event stack maize by Southern analyses.
Expression of the events
The applicant provided two studies, not previously assessed by the GMO Panel, on protein
expression levels of the five-event stack maize Bt11 9 MIR604 9 1507 9 5307 9 GA21 and the
corresponding single events. The data provided in one of these studies is considered of limited value
since derived from plants grown in one location during one season. Therefore, these data are not
representative and not in line with the applicable GMO Panel guidelines (EFSA GMO Panel, 2011a).
Hence, the GMO Panel has not taken these data into account for the risk assessment.
The other study contains data derived from plants harvested from a field trial at three locations in
Argentina in the 2012–2013 growing season and is therefore in line with the applicable GMO
Panel guidelines. Cry1Ab, PAT, mCry3A, PMI, Cry1F, eCry3.1Ab and mEPSPS protein levels in this study
were analysed by ELISA. Samples analysed included leaf (V6 and R1), root (V6 and R1), whole plant
(V6 and R1), pollen (R1) and grain (R6 and senescence) not treated with intended herbicides. The
levels of all the newly expressed proteins in the five-event stack and the corresponding singles are
comparable in all examined tissues except for PAT and PMI which showed the expected higher levels in
the stack resulting from the combination of events Bt11 and 1507 (producing PAT) and the
combination of events MIR604 and 5307 (producing PMI) respectively. Therefore, the results are as
expected (see Section 3.3.1.3).
Compositional analysis
The applicant provided a study on the compositional analysis of grain and forage of maize
Bt11 9 MIR604 9 1507 9 5307 9 GA21. The data were obtained from field trials performed at eight
locations in the USA in 2009. At each location, three materials were grown: the five-event stack maize
and a non-GM comparator, both treated with maintenance pesticides, and the five-event stack maize
treated with the intended herbicides. None of the differences in levels of nutritional compounds
between the five-event stack maize and the non-GM comparator was found to raise food/feed safety
issues. The GMO Panel notes that non-GM reference varieties were not included in the field trials and
thus, the design of the field trials does not comply with the EFSA guidance applicable for application
EFSA-GMO-DE-2011-103 (EFSA GMO Panel, 2011a). Therefore, the GMO Panel did not take the study
into account for the risk assessment.
Agronomic and phenotypic characteristics
The applicant provided a study on the agronomic and phenotypic characteristics of maize
Bt11 9 MIR604 9 1507 9 5307 9 GA21. The data were collected from a field trial study performed at
eight locations in the USA in 2009. At each location, two materials were grown in a randomised
complete block design with four replicates: the five-event stack maize and a non-GM comparator, both
treated with maintenance pesticides. None of the differences in agronomic and phenotypic
characteristics between the five-event stack maize and the non-GM comparator was found to raise
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safety issues. The GMO Panel notes that the five-event stack maize treated with the intended
herbicides and non-GM reference varieties were not included in the field trials and thus, the design of
the field trial does not comply with the EFSA guidance applicable for application EFSA-GMO-DE-2011-
103 (EFSA GMO Panel, 2011a). Therefore, the GMO Panel did not take the study into account for the
risk assessment.
90-day feeding study in rats
The applicant provided a 90-day study in which pair-housed RccHan:WIST rats (10/sex per group)
were randomly allocated to four groups and fed balanced diets containing approximately 10% or
41.5% (weight/weight) milled grain from maize Bt11 9 MIR604 9 1507 9 5307 9 GA2124 and the
respective same amount of a comparator. The study was conducted in accordance with OECD (1998)
and in compliance with the OECD Principles of Good Laboratory Practice (GLP). The GMO Panel notes
that the test material was derived from maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 by
segregating out event MIR162. No information was provided on the treatment of GM maize with the
intended herbicides. Moreover, no information was provided on the analytical composition of the GM
and control maize or on the homogeneity of the test diets.
The statistical analysis (two-sided one-way analysis of variance (ANOVA) and, for organ weights,
analysis of covariance using terminal kill body weight as covariate; all tests at 5% significance)
compared each of the two test groups with the respective control. The individual animal was
considered the experimental unit, except for feed consumption and related parameters (feed
utilisation). No intercurrent deaths occurred and no test diet-related clinical signs were seen. The
sporadic statistically significant differences observed between the test groups and their controls in
body weight, body weight gain and feed consumption are considered not to be treatment-related.
Overall feed utilisation (weeks 1–13) was decreased to a limited extent (~8%) in males given the 10%
test diet as compared to their controls. This reduction was not associated with changes in the terminal
body weight; therefore, it is considered not to be adverse. The isolated findings in a few functional
observational battery parameters25 and the minimally increased body temperature in females given the
41.5% test diet as compared to their controls (38.6 vs 38.0°C) are considered not to be adverse.
Regarding clinical pathology, the statistically significant differences26 observed between the rats given
the test diets and their controls were minimal, not associated with changes in related endpoints and
therefore are considered not to be adverse. Organ weight changes27 observed in rats given the 41.5%
test diet are considered not adverse based on the fact that no histopathological changes other than
common background findings were observed in the affected organs in these groups. No gross
pathology findings were noted related to the administration of the test diets; no test diet related
differences were noted in incidence and severity of the histopathological findings between the groups.
Based on the results and the considerations above, the GMO Panel concludes that in this study no
adverse effects were observed in rats given diets including up to 41.5% maize Bt11 9 MIR604 9
1507 9 5307 9 GA21 for 90 days.
42-day broiler study
A total of 540 (270 per sex) one-day-old chicken broilers (Ross 344 male 9 Ross 708 female) were
randomly allocated to three dietary groups with 180 chicks per treatment (12 pens/treatment, half for
each sex, 15 birds/pen) and fed balanced diets28 containing up to 64% maize Bt11 9 MIR604 9
1507 9 5307 9 GA21 grain (test item) or from the comparator (control diet) or the commercial non-
GM maize reference variety NCSU 2009 (reference diet). Diets (as crumbled pellets or pellets) and
water were offered ad libitum.
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24 Identity confirmed by ELISA.
25 Lower foregrip strength in females given the 10% test diet; higher motor activity measurements at the 6- to 10-minute time
point in males given 10% test diet; and lower number of movements in males given the 41.5% test diet at the 26- to 30- and
31- to 35-minute intervals.
26 4% higher albumin in males and 1% higher sodium in females given the 10% test diet; 4% higher calcium in males and
females given 41.5% test diet; 29% higher glucose, 27% lower AST, 21% lower ALP, 11% lower creatinine, 7% lower urea,
2% lower chloride and 1% lower sodium in males given the 41.5% test diet; 8% higher albumin and 6% higher total proteins
in females given the 41.5% test diet.
27 Higher mean absolute and relative testis weights and lower mean absolute and relative ovary and uterus weights (around
14% and 29%, respectively). It is noted that the mean weight of testes of the control at 41.5% is lower than that of the
control group at 10% and the mean weight of uterus in controls at 41.5% is higher than that of the control group at 10%.
28 Starter (0–15); grower (16–34); finisher (35–49).
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The data were analysed with one- or two-way ANOVA (main factors: sex and diet). No statistically
significant differences between the group fed test and control diets were observed in overall mortality
(less than 2%), body weights, feed consumption and feed conversion rates feed conversion ratio
among broilers fed the test, control and reference diets. Moreover, no statistically significant
differences were observed in the carcass portions absolute and relative weights. However, the GMO
Panel considered that a repeated measurement model should have been used for the analysis,
including time and time-by-treatment interaction as additional fixed effects.
The GMO Panel notes that this study was not conducted according to GLP standards, and information
regarding the treatment of test material with appropriate intended herbicides is missing; moreover, it is
noted that the test material was derived from maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21
by segregating out event MIR162.
Based on the results and the above considerations, the GMO Panel concludes that in this study no
adverse effects were observed in boilers fed diets containing up to 64% maize Bt11 9 MIR604 9
1507 9 5307 9 GA21 grain. Moreover, the measured performance endpoints were similar between
groups of animals fed balanced diets containing maize Bt11 9 MIR604 9 1507 9 5307 9 GA21 and
the controls.
Endogenous LTP allergen assessment
The applicant provided spontaneous information where LTP levels in maize Bt11 9 MIR604 9
1507 9 5307 9 GA21 were compared to those in a non-GM comparator and commercial reference
varieties. No changes in expression levels raising concern were identified.
3.4.2.4. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the single maize events has
been previously demonstrated (see Table 2). Integrity of the events was demonstrated in maize
Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 (Section 3.3.1.2), the previously assessed maize
subcombinations (Table 2) and also in the newly assessed data submitted for the five-event stack
maize Bt11 9 MIR604 9 1507 9 5307 9 GA21 (Section 3.4.2.3). The GMO Panel finds no reasons to
expect the loss of integrity of the events in the maize subcombinations not previously assessed.
3.4.2.5. Expression of the events
The GMO Panel assessed whether the combination of any of the six events by conventional
crossing could result in significant changes in expression levels of the newly expressed proteins, as this
could indicate an interaction between the events. Based on current knowledge of the molecular
elements introduced, there is no reason to expect interactions that would affect the levels of the newly
expressed proteins in the subcombinations compared with those in the single maize events. This
assumption was confirmed by comparing the levels of the newly expressed proteins of each single
maize event with those of the six-event stack maize and of a subcombination (five-event stack maize,
Section 3.4.2.3). The levels in both stacks were comparable to the respective single events except for
the expected higher levels of PAT and PMI. Therefore, there is no indication of an interaction
manifesting at protein expression level. This supports the conclusion that interactions affecting
expression levels of the newly expressed proteins are not expected in the maize subcombinations not
previously assessed.
3.4.2.6. Potential interactions between the events
The GMO Panel assessed the potential for interactions between maize events in the 34
subcombinations not previously assessed (Table 8), taking into consideration the intended traits and
unintended effects. Based on the known biological functions of the individual newly expressed proteins
(Table 4), there is currently no expectation for possible interactions relevant for the food/feed or
environmental safety between these proteins in those subcombinations. The GMO Panel also took into
account all the intended and potential unintended effects considered in the assessment of the six
single events, the previously assessed subcombinations (Table 2), the newly assessed five-event
subcombination (Section 3.4.2.3) and the six-event stack maize. It is concluded that none of these
events would raise safety concerns when combined in any of these maize subcombinations. The GMO
Panel considers that no further data are needed to complete the assessment of subcombinations from
the six-event stack maize.
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3.4.3. Conclusion
Since no new safety concerns were identified for the previously assessed 22 subcombinations, the
GMO Panel considers that its previous conclusions on these maize subcombinations remain valid. The
remaining 34 subcombinations included in the scope of application EFSA-GMO-DE-2011-103 have not
been previously assessed; for three of these, the applicant provided new information which was
considered by the GMO Panel. For the 34 subcombinations, the GMO Panel assessed the possibility of
interactions between the events and concludes that these combinations would not raise safety
concerns. These subcombinations are therefore expected to be as safe as and nutritionally equivalent
to the single maize events, the previously assessed subcombinations and the six-event stack maize.
3.5. Post-market monitoring29
3.5.1. Post-market monitoring of GM food/feed
The GMO Panel concludes that six-event stack maize, as described in this application, is nutritionally
equivalent to and as safe as the non-GM comparator and the non-GM reference varieties tested
(Section 3.3.5). Twenty-two of the subcombinations have been previously assessed and no safety
concerns were identified. The 34 subcombinations not previously assessed and included in the scope
of application EFSA-GMO-DE-2011-103 are expected to be as safe as and nutritionally equivalent to the
single maize events, the previously assessed maize subcombinations and the six-event stack maize
(Section 3.4.3). Therefore, the GMO Panel considers that post-market monitoring of food and feed
from the six-event stack maize and its subcombinations, as described in this application, is not
necessary.
3.5.2. Post-market environmental monitoring
The objectives of a post-market environmental monitoring (PMEM) plan, according to Annex VII of
Directive 2001/18/EC, are to: (1) confirm that any assumption regarding the occurrence and impact of
potential adverse effects of the GMO, or its use, in the ERA are correct; and (2) identify the occurrence
of adverse effects of the GMO, or its use, on human health or the environment that were not
anticipated in the ERA.
Monitoring is related to risk management, and thus a final adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientific rationale of the post-
market environmental monitoring plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA does not identify potential adverse environmental effects from the six-event stack
maize, no case-specific monitoring is required.
The PMEM plan proposed by the applicant for the six-event stack maize includes: (1) the
description of an approach involving operators (federations involved in maize import and processing),
reporting to the applicant, via a centralised system, any observed adverse effect(s) of GMOs on human
health and the environment; (2) a coordinating system newly established by EuropaBio for the
collection of the information recorded by the various operators; and (3) the review of relevant
scientific publications retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The
applicant proposes to submit a post-market environmental monitoring report on an annual basis and a
final report at the end of the authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of the six-event stack maize and its subcombinations. The GMO Panel agrees
with the reporting intervals proposed by the applicant in its PMEM plan.
3.5.3. Conclusion on post-market monitoring
No post-market monitoring of food and feed is necessary. The scope of the PMEM plan provided by
the applicant and the reporting intervals are in line with the intended uses of maize
Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 and its subcombinations.
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4. Overall conclusions and recommendations
No new information on the six single maize events Bt11, MIR162, MIR604, 1507, 5307 and GA21
leading to a modification of the original conclusions on their safety were identified.
The molecular characterisation, the comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single maize events and of the newly expressed proteins in the six-event
stack maize does not give rise to food/feed safety and nutritional concerns. The GMO Panel concludes
that the six-event stack maize, as described in this application, is as safe as and nutritionally equivalent
to its non-GM comparator and the non-GM reference varieties tested, and that post-market monitoring
of food and feed is not necessary.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from the six-event stack maize into the environment.
Since no new data on the 22 subcombinations previously assessed (10 two-event stacks, 9 three-
event stacks and 3 four-event stacks) that would lead to a modification of the original conclusions on
their safety were identified, the GMO Panel considers that its previous conclusions on these maize
stacks remain valid.
The remaining 34 subcombinations included in the scope of application EFSA-GMO-DE-2011-103
have not been previously assessed; for three of them, the applicant provided new information that
was considered by the GMO Panel. The GMO Panel assessed possible interactions between the events
in the 34 subcombinations, and concludes that these combinations of events Bt11, MIR162, MIR604,
1507, 5307 and GA21 would not raise safety concerns. These subcombinations are therefore expected
to be as safe as and nutritionally equivalent to the maize single events, the previously assessed
subcombinations and the six-event stack maize.
Given the absence of safety concerns for foods and feeds from the six-event stack maize and all its
subcombinations, the GMO Panel considers that post-market monitoring of these products is not
necessary.
The PMEM plan provided by the applicant and the reporting intervals are in line with the intended
uses of the six-event stack maize and its subcombinations.
Documentation provided to EFSA
1) Letter from the Competent Authority of Germany received 16 December 2011 concerning a
request for authorisation for the placing on the market of maize Bt11 9 MIR162 9 MIR604
9 1507 9 5307 9 GA21 (reference EFSA-GMO-DE-2011-103) submitted in accordance with
Regulation (EC) No 1829/2003 by Syngenta.
2) Application EFSA-GMO-DE-2011-103 validated by EFSA, 18 August 2014.
3) EFSA stops the clock on 20 August 2014 due to the ongoing risk assessment of application
EFSA-GMO-DE-2011-95.
4) EFSA maintains the clock stopped on 7 May 2015 due to the inconclusive opinion of the
maize single event 5307 (application EFSA-GMO-DE-2011-95).
5) Receipt of spontaneous information from the applicant, 20 July 2015.
6) Request for supplementary information to the applicant, 21 September 2015.
7) Receipt of supplementary information from the applicant, 29 September 2015.
8) Receipt of supplementary information from the applicant, 16 December 2015.
9) Request for supplementary information to the applicant, 13 March 2018.
10) Request for supplementary information to the applicant, 21 March 2018.
11) Receipt of supplementary information from the applicant, 3 May 2018.
12) Request for supplementary information to the applicant, 4 May 2018.
13) Receipt of supplementary information from the applicant, 25 May 2018.
14) Request for supplementary information to the applicant, 8 June 2018.
15) Receipt of supplementary information from the applicant, 7 June 2018.
16) Request for supplementary information to the applicant, 19 June 2018.
17) Request for supplementary information to the applicant, 18 July 2018.
18) Receipt of supplementary information from the applicant, 6 August 2018.
19) Receipt of supplementary information from the applicant, 29 August 2018.
20) Receipt of supplementary information from the applicant, 17 September 2018.
21) Request for supplementary information to the applicant, 9 October 2018.
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22) Request for supplementary information to the applicant, 28 November 2018.
23) Receipt of supplementary information from the applicant, 17 December 2018.
24) Receipt of supplementary information from the applicant, 7 February 2019.
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Appendix A – Protein expression data
Mean, standard deviation and range of protein levels (lg/g dry weight) from maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21, Bt11, MIR162,
MIR604, 1507, 5307 and GA21 unsprayed tissues from field trials performed across three locations in the USA in 2012 (n = 14 or n = 15).(a)
Protein Event(s) Leaf (V6) Leaf (R1) Root (V6) Root (R1)
Whole plant
(V6)
Whole plant
(R1)
Pollen (R1) Grain (R6)
Grain
(senescence)
Cry1Ab Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
107.0(b)  34.8(c)
(53.6–175.0)(d)
49.38  20.51
(15.48–81.98)
30.73  8.23
(19.23–41.43)
19.77  3.82
(15.06–26.74)
89.89  21.30
(54.31–120.56)
29.19  10.19
(12.45–47.79)
0.07  0.02
(0.05–0.13)
2.68  0.45
(1.93–3.32)
2.56  0.36
(1.81–2.96)
Bt11 93.2  29.9
(48.3–128.0)
42.47  14.41
(19.90–63.86)
32.03  7.96
(22.67–45.85)
18.71  1.97
(16.10–22.68)
81.59  20.08
(51.72–113.87)
23.76  8.71
(10.27–36.23)
0.07  0.02
(0.05–0.13)
2.47  0.37
(1.84–3.01)
2.45  0.56
(1.25–3.58)
PAT Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
5.39  1.55
(2.64–7.91)
6.23  1.06
(4.79–8.26)
0.92  0.41
(0.36–1.54)
0.74  0.12
(0.54–0.95)
3.78  0.67
(2.32–4.97)
3.47  0.85
(2.24–4.60)
0.15  0.05(a)
(0.12–0.19)
–
(< LOQ)
–
(< LOQ)
Bt11 0.47  0.13
(0.27–0.75)
0.51  0.08
(0.33–0.64)
0.76  0.30
(0.30–1.19)
0.70  0.12
(0.48–0.87)
0.55  0.11
(0.38–0.82)
0.56  0.06
(0.46–0.70)
–
(< LOQ)
–
(< LOQ)
–
(< LOQ)
1507 4.74  1.36
(2.32–7.76)
5.61  0.96
(3.52–6.96)
0.54  0.26
(0.11–1.0)
0.26  0.07
(0.15–0.38)
3.65  1.25
(1.42–5.79)
2.89  1.08
(1.68–5.28)
–
(< LOQ)
–
(< LOQ)
–
(< LOQ)
Vip3Aa20 Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
134.79  18.60
(108.03–161.56)
145.46  40.70
(90.20–228.15)
92.22  35.36
(53.67–150.70)
48.43  5.67
(39.55–57.76)
156.08  40.40
(64.26–235.51)
124.81  22.70
(85.08–169.36)
112.85  13.50
(90.43–135.15)
99.70  19.01
(75.82–143.22)
90.52  15.81
(69.33–115.87)
MIR162 168.81  42.80
(109.36–243.83)
134.82  39.10
(70.10–207.68)
82.54  27.01
(44.58–130.06)
45.10  7.30
(32.10–58.20)
151.58  37.60
(68.01–195.90)
138.00  33.60
(91.70–203.0)
115.83  15.60
(82.89–141.51)
101.71  15.0
(80.56–133.83)
91.80  21.61
(40.30–128.0)
PMI(e) Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
23.69  4.97
(15.94–33.59)
21.59  4.53
(11.13–28.03)
15.22  4.03
(9.18–23.64)
7.46  1.33
(5.25–8.97)
24.37  5.09
(12.43–30.69)
16.61  5.75
(8.55–24.86)
134.15  15.90
(102.18–162.43)
6.38  1.04
(4.67–8.31)
5.66  0.85
(4.70–7.16)
MIR162 8.01  0.71
(7.13–9.33)
8.79  1.10
(6.93–11.29)
4.47  0.92
(2.85–6.26)
2.23  0.58
(1.45–3.39)
7.66  1.34
(5.36–9.39)
7.44  2.27
(4.09–10.54)
6.74  1.32
(3.91–8.85)
2.10  0.28
(1.78–2.68)
1.91  0.32
(1.54–2.63)
MIR604 11.35  1.69
(9.58–15.25)
10.35  2.11
(8.02–14.73)
7.59  1.12
(5.97–10.28)
3.94  0.91
(2.76–5.83)
12.18  2.81
(9.28–19.70)
9.22  2.64
(6.24–14.39)
65.89  7.80
(45.99–78.64)
3.14  0.58
(1.96–4.10)
2.94  0.65
(2.27–4.50)
5307 3.37  0.70
(2.56–4.80)
4.45  0.70
(3.21–6.08)
3.25  0.78
(2.31–5.41)
2.19  0.80
(1.33–3.81)
3.65  0.81
(2.57–5.60)
4.18  0.68
(3.11–5.35)
68.69  7.01
(56.08–80.99)
1.82  0.36
(1.30–2.63)
1.50  0.33
(0.94–2.10)
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Protein Event(s) Leaf (V6) Leaf (R1) Root (V6) Root (R1)
Whole plant
(V6)
Whole plant
(R1)
Pollen (R1) Grain (R6)
Grain
(senescence)
mCry3A Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
13.37  2.14
(9.64–16.78)
10.60  3.38
(4.74–16.78)
13.74  3.01
(9.79–19.79)
11.10  1.39
(9.23–14.29)
11.71  1.83
(8.16–14.34)
7.34  1.54
(4.90–10.01)
0.09  0.03
(0.04–0.15)
0.44  0.24
(0.26–0.97)
0.33  0.10
(0.26–0.64)
MIR604 15.66  2.49
(11.64–21.05)
13.78  1.89
(10.76–17.11)
17.24  4.35
(10.43–25.64)
12.86  2.32
(8.90–17.43)
13.98  2.88
(8.50–18.47)
10.48  2.43
(6.21–13.83)
0.06  0.02
(0.04–0.10)
0.76  0.30
(0.26–1.32)
0.64  0.21
(0.28–0.99)
Cry1F Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
26.69  5.39
(17.89–33.98)
20.66  3.32
(14.48–27.66)
10.67  3.73
(5.12–20.26)
7.28  1.30
(5.63–9.50)
20.56  1.88
(16.19–23.11)
13.02  3.34
(7.89 –20.20)
35.08  3.12
(31.86–44.30)
4.92  1.03
(3.64–7.90)
4.42  0.92
(3.38–7.03)
1507 26.86  4.09
(22.46–34.94)
19.62  3.79
(14.14–26.91)
9.66  2.31
(4.15–12.95)
6.54  1.25
(4.79–8.67)
19.80  2.81
(13.86–24.28)
13.40  2.55
(8.96–17.80)
34.87  5.05
(25.99–42.52)
4.99  0.98
(4.09–7.69)
4.48  0.90
(3.26–5.99)
eCry3.1Ab Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
104.10  31.70
(66.02–196.15)
43.07  19.70
(9.40–68.82)
26.54  10.95
(9.48–43.68)
7.35  1.89
(3.83–9.83)
125.30  32.10
(68.42–185.74)
32.71  12.25
(11.65–50.92)
0.12  0.03
(0.09–0.16)
4.29  1.21(a)
(2.10–6.06)
3.38  1.06
(2.27–6.50)
5307 110.57  20.80
(74.50–151.64)
58.86  10.75
(42.57–80.13)
28.08  14.16
(7.80–57.01)
9.19  2.35
(6.07–13.54)
123  40.60
(73.34–197.0)
53.81  12.65
(31.57–73.64)
0.12  0.03
(0.08–0.16)
6.68  1.72
(4.48–10.09)
4.09  0.96
(2.55–6.03)
mEPSPS Bt11 3 MIR162 3
MIR604 3 1507 3
5307 3 GA21
64.64  31.38
(20.32–108.57)
69.09  23.04
(33.58–109.20)
37.70  8.69(a)
(30.0–51.30)
18.0(a) 63.53  19.94
(31.73–96.15)
–
(< LOQ)
400.90  64.50
(298.02–500.78)
7.86  0.61(a)
(7.20–8.70)
5.64  0.08(a)
(5.58–5.69)
GA21 61.82  25.07
(26.38–111.81)
81.40  14.23
(59.10–103.0)
36.60  14.57(a)
(25.80–61.0)
20.90  5.08(a)
(17.90–26.80)
50.20  14.54
(32.47–74.06)
–
(< LOQ)
369.46  50.60
(296.0–469.41)
8.48  1.47(a)
(6.07–9.97)
6.85(a)
(a): Number of samples is n = 14 or n = 15 except for: n = 2 for PAT in pollen of the six-event stack; n = 3 for eCry3.1Ab in pollen of the six-event stack; n = 9 for eCry3.1Ab in pollen of 5307;
n = 5 for mEPSPS in root(V6) of the six-event stack and GA21; n = 1 and n = 3 for mEPSPS in root (R1) of the six-event stack and GA21, respectively; n = 5 for mEPSPS in grain(R6) of the
six-event stack and GA21; n = 2 and n = 1 for mEPSPS in grain (senescence) of six-event stack and GA21, respectively.
(b): Mean.
(c): Standard deviation.
(d): Range.
(e): PMI levels in maize Bt11 9 MIR162 9 MIR604 9 1507 9 5307 9 GA21 are a sum of two protein variants; one expressed in MIR162 and 5307 and another expressed in MIR604. These two
PMI variants differ by two amino acids.
–: Not determined due to all measurements below LOQ.
LOQ: limit of quantification.
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